30.2 C
New York
Sunday, June 14, 2026

Tag: presentations

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin UseNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A...

S&P Global to Present at Mizuho Technology Conference 2026 on June 10, 2026

Session will be WebcastNEW YORK, June 5, 2026 /PRNewswire/ -- Mark Grant, Senior Vice President of Investor Relations and Treasurer of S&P Global (NYSE: SPGI),...

Prestige Consumer Healthcare Inc. to Participate in the Oppenheimer Annual Consumer Growth and E-Commerce Conference

TARRYTOWN, N.Y., June 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference virtually on Monday, June 8, 2026 at 9:45 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the following link:

Bimergen Energy (BESS) to Present Path to $400 Million Revenues in The Small Cap Showcase & Water Tower Research Insights, June 9, 2026

Newport Beach, CA, June 05, 2026 (GLOBE NEWSWIRE) -- Bimergen Energy Corporation [NYSE American: BESS, BESS.WS] today announced that Bob Brilon, Co-CEO will participate in The Small Cap Showcase & WTR Insights, taking place on June 9, 2026, in New York City.

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly...

Prologis to Announce Second Quarter 2026 Results July 16, 2026

SAN FRANCISCO, June 4, 2026 /PRNewswire/ -- Prologis, Inc. (NYSE: PLD) will host a webcast and conference call with senior management to discuss its...

Resideo Provides Update on Planned Spin-Off of ADI Global Distribution

Files Amended Form 10 Registration StatementAnnounces Scheduling Details for Resideo and ADI Investor DaysReaffirms Previously Announced Second Quarter and Full Year 2026 Outlook; Releases...

IDBS i3 2026 forum in Boston showcases real-world customer outcomes in data-driven BioPharma

WOKING, United Kingdom, June 4, 2026 /PRNewswire/ -- IDBS, a Danaher company and leading provider of cloud software for BioPharma organizations, today shared outcomes from...

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

EOG Resources to Present at Upcoming Conference

HOUSTON, June 3, 2026 /PRNewswire/ -- EOG Resources, Inc. (EOG) is scheduled to present at the J.P. Morgan Energy, Power, Renewables and Mining Conference at...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPresentations